Cytosorbents
CTSO· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -29.8% in FY2025
Phillip P. Chan, MD, PhD is the CEO of Cytosorbents and was paid $808.4K in FY2025 (Dec), down 10%.
Pay$100 in the stock at the end of FY20 → $8
Executives4
See all- 1Phillip P. Chan, MD, PhDChief Executive OfficerFY2025
- 2Vincent J. Capponi, MSPresident and Chief Operating OfficerFY2025
- 3Efthymios N. Deliargyris, MDChief Medical OfficerFY2025
- 4Peter J. MarianiChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allCytosorbents paid its 4 named executives $2.8M in total in FY2025 (Dec). CEO Phillip P. Chan, MD, PhD was paid $808.4K of that.
| Name | |||
|---|---|---|---|
| Phillip P. Chan, MD, PhDChief Executive Officer | |||
| Vincent J. Capponi, MSPresident and Chief Operating Officer | |||
| Efthymios N. Deliargyris, MDChief Medical Officer | |||
| Peter J. MarianiChief Financial Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Cytosorbents. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Activity
Filings6
See all| Proxy statement | DEF 14A | Jun 25, 2026 | FY2025 |
| Annual report | 10-K | Mar 30, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 23, 2025 | FY2024 |
| Annual report | 10-K | Mar 31, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 19, 2024 | FY2023 |
| Annual report | 10-K | Mar 15, 2024 | FY2023 |
